Sanofi

Princeton University

Xin Chen

Govindan Subramanian

Nicolas Baurin

Han Li

Matthew Davison

Dorothea Kominos

Alla Pritsker

Jie Zhang

Bonnie L Bassler

Stephen R Cooper

Stephan Schauder

Frederick M Hughson

The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg-Bradykinin and des-Arg-Kallidin-like peptide.

Nucleic acids encoding antibodies to Kallidin and des-Arg-Kallidin and host cells comprising the same

[object Object]

A crystal comprising LuxP is obtained, and a binding site for autoinducer-2 (AI-2) identified. The X-ray crystallographic data for LuxP and a LuxP-AI-2 complex is determined and used in a drug discovery method. Pharmaceutical compositions comprising ligands identified by such drug discovery methods are used to treat bacterial infections.

Crystals of LuxP and complexes thereof

Growing community of inventors

Edison, NJ, United States of America

Xin Chen